JW Pharmaceutical Corp (KO:001067) — Stock Price
JW Pharmaceutical Corp (KO:001067) is currently trading at ₩44200.00 KRW, up 1.14% today. Over the past 52 weeks, shares have ranged between ₩41000.00 and ₩63300.00. This page tracks JW Pharmaceutical Corp's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 001067 market cap.
JW Pharmaceutical Corp (001067) Stock Price Chart — Daily History & Trading Volume
The chart below tracks JW Pharmaceutical Corp's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
JW Pharmaceutical Corp Income Statement — Revenue, Profit & Earnings by Year
JW Pharmaceutical Corp's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩719.38 Billion | ₩748.53 Billion | ₩684.35 Billion | ₩606.58 Billion | ₩547.34 Billion |
| Cost of Revenue | ₩395.88 Billion | ₩412.98 Billion | ₩396.40 Billion | ₩372.21 Billion | ₩369.81 Billion |
| Gross Profit | ₩323.50 Billion | ₩335.54 Billion | ₩287.95 Billion | ₩234.38 Billion | ₩177.53 Billion |
| Research & Development | ₩36.24 Billion | ₩33.67 Billion | ₩33.74 Billion | ₩19.88 Billion | ₩22.94 Billion |
| SG&A | ₩157.92 Billion | ₩152.64 Billion | ₩126.74 Billion | ₩115.34 Billion | ₩92.52 Billion |
| Total Operating Expenses | ₩636.64 Billion | ₩647.61 Billion | ₩621.57 Billion | ₩575.39 Billion | ₩548.66 Billion |
| Operating Income | ₩82.73 Billion | ₩100.92 Billion | ₩62.78 Billion | ₩31.20 Billion | ₩-1.32 Billion |
| EBITDA | — | — | ₩71.59 Billion | ₩43.98 Billion | ₩15.07 Billion |
| EBIT | — | — | ₩60.49 Billion | ₩30.85 Billion | ₩-1.32 Billion |
| Interest Expense | ₩10.03 Billion | ₩12.56 Billion | ₩9.39 Billion | ₩7.34 Billion | ₩7.59 Billion |
| Income Before Tax | ₩82.42 Billion | ₩54.84 Billion | ₩45.36 Billion | ₩20.53 Billion | ₩-13.21 Billion |
| Income Tax Expense | — | — | ₩15.51 Billion | ₩21.97 Billion | ₩2.07 Billion |
| Net Income | ₩65.04 Billion | ₩37.01 Billion | ₩31.89 Billion | ₩-967.85 Million | ₩-15.24 Billion |
JW Pharmaceutical Corp Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes JW Pharmaceutical Corp's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩604.60 Billion | ₩645.04 Billion | ₩627.97 Billion | ₩633.05 Billion | ₩549.09 Billion |
| Total Current Assets | ₩306.41 Billion | ₩378.09 Billion | ₩425.46 Billion | ₩366.45 Billion | ₩299.33 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩22.12 Billion | ₩78.29 Billion | ₩115.78 Billion | ₩32.30 Billion | ₩44.84 Billion |
| Net Receivables | ₩135.50 Billion | ₩159.38 Billion | ₩147.52 Billion | ₩151.78 Billion | ₩122.83 Billion |
| Inventory | ₩111.73 Billion | ₩106.09 Billion | ₩111.67 Billion | ₩102.53 Billion | ₩101.20 Billion |
| Property, Plant & Equipment | — | — | ₩123.05 Billion | ₩118.39 Billion | ₩185.57 Billion |
| Goodwill | ₩0.00 | ₩1.40 Billion | — | — | — |
| Total Liabilities | ₩275.11 Billion | ₩379.60 Billion | ₩402.21 Billion | ₩444.51 Billion | ₩341.62 Billion |
| Total Current Liabilities | ₩208.62 Billion | ₩286.93 Billion | ₩380.13 Billion | ₩282.68 Billion | ₩234.75 Billion |
| Long-term Debt | ₩25.10 Billion | ₩30.00 Billion | — | ₩120.74 Billion | ₩73.58 Billion |
| Net Debt | ₩56.07 Billion | ₩127.23 Billion | ₩172.54 Billion | ₩209.18 Billion | ₩169.60 Billion |
| Total Stockholder Equity | ₩329.49 Billion | ₩265.44 Billion | ₩240.35 Billion | ₩201.19 Billion | ₩207.49 Billion |
| Retained Earnings | ₩164.12 Billion | ₩113.03 Billion | ₩89.13 Billion | ₩58.59 Billion | ₩65.08 Billion |
JW Pharmaceutical Corp Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how JW Pharmaceutical Corp generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩79.39 Billion | ₩87.16 Billion | ₩56.76 Billion | ₩18.12 Billion | ₩63.05 Billion |
| Capital Expenditures | ₩28.14 Billion | ₩40.71 Billion | ₩9.92 Billion | ₩7.47 Billion | ₩12.39 Billion |
| Free Cash Flow | ₩51.25 Billion | ₩46.45 Billion | ₩44.41 Billion | ₩5.22 Billion | ₩48.02 Billion |
| Investing Cash Flow | — | — | ₩-18.92 Billion | ₩-22.87 Billion | ₩-79.43 Billion |
| Financing Cash Flow | — | — | ₩-36.91 Billion | ₩27.20 Billion | ₩-14.01 Billion |
| Dividends Paid | ₩-9.67 Billion | ₩8.81 Billion | ₩7.35 Billion | ₩7.15 Billion | ₩6.95 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩19.10 Billion | ₩22.57 Billion | ₩16.84 Billion | ₩16.11 Billion | ₩20.69 Billion |
| Change in Cash | ₩-5.48 Billion | ₩-17.99 Billion | ₩531.45 Million | ₩22.92 Billion | ₩-31.41 Billion |
JW Pharmaceutical Corp Earnings History — EPS Actual vs. Analyst Estimates
Track JW Pharmaceutical Corp's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 05, 2026 | — | — | — |
| Feb 05, 2026 | — | — | — |
| Nov 04, 2025 | — | — | — |
| Jul 30, 2025 | — | — | — |
| May 07, 2025 | — | — | — |
| Feb 03, 2025 | — | — | — |
| Nov 06, 2024 | — | — | — |